Mosliciguat
Pulmonary Hypertension associated with Interstitial Lung Disease
Proof of ConceptActive
Key Facts
Indication
Pulmonary Hypertension associated with Interstitial Lung Disease
Phase
Proof of Concept
Status
Active
Company
About Roivant Sciences
Founded in 2014, Roivant Sciences operates through a unique 'Vant' model, creating nimble subsidiary companies focused on specific therapeutic areas including Immunovant (autoimmune diseases), Priovant (severe autoimmune conditions), and Pulmovant (pulmonary diseases). The company has demonstrated strong execution with multiple successful Phase 3 trials and commercial launches, including VTAMA for plaque psoriasis. Roivant trades on NASDAQ under ticker ROIV and maintains a broad pipeline of investigational drugs across various therapeutic areas and development phases.
View full company profileOther Pulmonary Hypertension associated with Interstitial Lung Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| PH-ILD Program | Insmed | Phase 2a |